Quick Stats

Quick Stats

    You are here

    ChevronTexaco and Former CEO Contribute to Fight Cancer

    Oil giant and retired chairman, a survivor, donate $2.5 million.

    SAN RAMON, Calif. -- ChevronTexaco is contributing $1 million to the University of California, San Francisco (UCSF), to fight prostate and breast cancer, and former Chevron chairman and CEO Ken Derr and his wife Donna also are donating $1.5 million to UCSF to support prostate cancer research.

    "Our hope is that these funds will act as a catalyst for positive change in the battle against prostate and breast cancer," said David J. O'Reilly, chairman and CEO of ChevronTexaco.

    ChevronTexaco contributed $500,000 to the UCSF San Francisco Mammography Registry, a research resource that collects demographic, clinical and risk factor information to study and combat breast cancer. The other $500,000 from ChevronTexaco, along with the Derrs' gift, will establish the Ken and Donna Derr-ChevronTexaco Distinguished Professorship in Prostate Cancer, which will be held by Peter R. Carroll, M.D., chair of UCSF's Department of Urology.

    "Donna and I are pleased to contribute to the groundbreaking work of Dr. Carroll. This contribution reflects a shared commitment with UCSF to prevent and cure prostate cancer and improve the quality of life for men undergoing treatment," said Derr, who was treated at UCSF in 1998 for prostate cancer.

    Derr retired in 1999 after almost 40 years with Chevron, including 11 years as chairman and CEO. To honor his years of service to the company, ChevronTexaco contributed $500,000 to UCSF in 2000 for prostate cancer research.

    UCSF is one of the world's premier health sciences universities, a leader in biomedical research, patient care, higher education and public service.

    "Discovering the fundamental biological processes underlying prostate cancer and translating those discoveries into new ideas for prevention, diagnosis and treatment is our primary emphasis," said Carroll. "These generous contributions allow us to continue our search for answers and allow those affected by prostate cancer to live longer, fuller lives."

    • About

    Related Content

    Related Content